<DOC>
	<DOCNO>NCT01805518</DOCNO>
	<brief_summary>Phosphodiesterase candidate Rx &amp; prevention cognitive psychotic disorder . Since caffeine target primarily PDE4 ( Phosphodiesterase subtype 4 ) , caffeine analog develop mimic action caffeine 's ability inhibit PDE-a , PDE4 , PDE5 adenosine-2 ( AD-2 ) limit side effect insomnia heighten anxiety . Sildenafil ( PDE-5 inhibitor ) fail enhance cognition schizophrenia . The study PDE-4 cognition Alzheimer 's dementia schizophrenia do use PDE-4 prototypal compound , rolipram , improve cognition rodent . Rolipram reverse memory deficit induce amyloid fragment Abeta25-35 Abeta1-40 peptide . In humans frequent side effect vomit hamper translational research . The clinical trial rolipram multiple sclerosis terminate prematurely due serious adverse event paradoxical increase MRI MS-specific brain lesion . However , PDE-4 remain paradigm cognition . Another strategy chemical moiety capable antagonize PDE-4 allosteric modulation , rather direct competitive inhibition hop minimize adverse event retain biological potency functional response PDE-4 Modulators . Dietary supplement PDE-4 effect advantage small investment need adequately study . Pharmacologically active chemical Sceletium specie mesembrine-type alkaloid proven PDE-4 activity . The PDE-4D knockout mouse enhance memory function mediate hippocampal neurogenesis via phosphorylated cAMP response element bind protein ( pCREB ) signaling . This study purpose delineate relationship PDE-4 cognition normal . pCREB possibly putative biomarker PDE-4 response CREB effector signal pathway PDE-4 . CREB close nuclear receptor represent BDNF ( Brain Derived Neurotrophic Factor ) PPAR ( Peroxisome Proliferator Activating Receptor ) complex . CREB change neuronal plasticity target pharmacological paradigm cognitive enhancement . This study use scelectium tortuosum manufacture Zembrin® . The finding control subject form basis design future study Zembrin® neurodegenerative disorder mark cognitive impairment Alzheimer 's Dementia Parkinson 's Disease .</brief_summary>
	<brief_title>Safety Study Effect Scelectium Tortuosum ( Zembrin® ) Aged Normals</brief_title>
	<detailed_description>1 . Contextual Background For past decade , converge evidence suggest target PD Phosphodiesterase cognition represent novel heuristic approach development dietary supplement drug candidate treatment prevention cognitive psychotic disorder . 1. . The early finding caffeine prototypal PD inhibitor target primarily PDE4 ( Phosphodiesterase subtype 4 ) stimulate synthesis caffeine analog improve upon pharmacokinetic profile benefits/risk ratio . 2. . The dual action caffeine inhibitor PDE-a , PDE4 PDE5 adenosine-2 ( AD-2 ) antagonist , exert multiple brain-behavior function include sleep , cognition , memory learning . It remain see whether caffeine analogue live therapeutic potential neurodegenerative disease bypass side effect insomnia heighten anxiety . Sildenafil ( Viagra R ) PDE-5 inhibitor indicate erectile dysfunction ( ED ) fail enhance cognition schizophrenia 3. . The full dosage range may explore study sildenafil . It noteworthy PDE-5 inhibition relate NMDA ( N-methyl-d-aspartic acid ) glutamatergic modulation . In conduct Pub Med search recent study point role PDE-4 diverse domains cognition : memory , attention , executive function , recall , visual-spatial task . We find converge evidence target PDE-4 novel approach towards treat cognitive deficit Alzheimer dementia schizophrenia 4. . Most preclinical study focus exclusively PDE-4 prototypal compound , rolipram . Rolipram improve memory consolidation , work memory information processing rodent specie subject variety cognitive task : radial arm maze , passive avoidance , delay arm water maze 5. . A recent study find rolipram , reverse deficit induce amyloid fragment Abeta25-35 Abeta1-40 peptide Morris water maze passive avoidance task 6. . In preclinical screen PDE-4 inhibitor , vomit mediate via activate area postema consistently note . Tolerability safety hamper significantly translation research PDE-4 inhibitor . The clinical trial rolipram multiple sclerosis terminate prematurely due serious adverse event paradoxical increase MS-specific brain lesion identify MRI 7. . Notwithstanding challenge translational research , molecular template PDE-4 remain highly viable paradigm cognition . Drug Design adopt another strategy develop chemical moiety capable antagonize PDE-4 pharmacological effect . Through allosteric modulation , rather direct competitive inhibition catalytic site domain PDE-4 , hope minimize adverse event retain biological potency functional response relevant pharmacological activity PDE-4 compound . 8. . The emergence PDE-4 Modulators ( PDE-4M ) attract attention . Dietary supplement possess molecular template requirement PDE-4 design strategy add advantage preliminary clinical study undertake disproportionately small investment . If preliminary result favorable , strategic advance GMP patent drug candidate predictable confer less fiscal clinical risk without compromise efficacy stipulation satisfy FDA criterion phase II Phase III trial . Our study Zembrin® formulation Scelectium Toruosum cognition expand earlier study protocol investigate effect Zembrin® Generalized Anxiety Disorder ( GAD ) . The pharmacologically active chemical Sceletium specie belong mesembrine-type alkaloid ; structure well characterize . Structure-activity relationship mesembrine-derivative alkaloid delineate in-vitro assay recombinant PDE-4 regard relative potency produce functional response . The IC50 mesembrine-HCL determine 20 microM 9. . The PDE-4D knockout mouse model provide evidence enhance memory function mediate hippocampal neurogenesis via phosphorylated cAMP response element bind protein ( pCREB ) signaling . 10. . Microinfusion lentiviral vector carry micro RNAs target long-form PDE4D isoforms directly bilateral dentate gyrus hippocampus mouse result improved performance score object recognition test , water maze radial arm maze . These consideration lead u organize pilot `` proof-of-concept study '' delineate relationship PDE-4 cognition normal control subject validate target PDE-4 modulating cognition function normal control subject . It noteworthy none preliminary study include measure cAMP signal clinical subject correlate brain-behavior interaction . With availability sensitive , reliable valid ELISA method assay pCREB , consider important examine pCREB putative biomarker PDE-4 response clinical subject treat Zembrin® . There emerge increase evidence support construct CREB effector signal pathway PDE-4 , target diverse class antidepressant 11. . CREB late molecular partner family nuclear receptor represent BDNF ( Brain derive neurotrophic factor ) PPAR ( Peroxisome Proliferator Activating Receptor ) complex 12. . CREB reflect change neuronal plasticity sensitive pharmacological paradigm cognitive enhancement . CREB signal integrates signal transduction relate neurotransmitter neuromodulators besides PDE-4 . Neuronal alpha-7 nicotinic receptor agonist A-582941 exerts cognitive effect interact phosphorylation CREB pathway ( 13 ) . The finding control subject form rational basis design control study Zembrin® neurodegenerative disorder mark cognitive impairment Alzheimer 's Dementia Parkinson 's Disease .</detailed_description>
	<criteria>Male female Age : 4565 Absence DSM IVR diagnosis As establish MiniPsychiatric Interview HAMD &lt; 8 Body Mass Index ( BMI ) &lt; 30.0 Not Suicidal Current ( past 2 month ) substance use disorder , Abuse Caffeine Severe nicotine dependence Abuse herbal dietary supplement Current plan pregnancy ( female ) A major DSM IVR psychiatric diagnosis . Serious unstable medical disorder : Recent myocardial ischemia infarction , unstable angina , uncontrolled hypertension , poor glycemic control Diabetes mellitus , Renal failure serious renal disease , Chronic active hepatitis , acute hepatitis , cirrhosis liver , AIDS Active malignancy Neurological disorder : epilepsy Recent Traumatic brain injury Active suicidal risk Cerebrovascular disorder : recent stroke Inability read write</criteria>
	<gender>All</gender>
	<minimum_age>45 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>CNSVS</keyword>
	<keyword>Tower London</keyword>
	<keyword>Letter-Number Test</keyword>
	<keyword>Trail Making Test</keyword>
	<keyword>Vital sign</keyword>
	<keyword>Mood</keyword>
	<keyword>Suicidal ideation</keyword>
	<keyword>ECG</keyword>
	<keyword>Physical exam</keyword>
	<keyword>Blood</keyword>
	<keyword>Urine ( Including pregnancy drug screen )</keyword>
	<keyword>Cytokines</keyword>
	<keyword>Side effect</keyword>
	<keyword>Brief Psychiatric Rating Scale</keyword>
	<keyword>Positive Negative Symptom Scale</keyword>
</DOC>